Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126063912 | 12606391 | 2 | F | 20160803 | 20160729 | 20160817 | EXP | JP-SUN PHARMACEUTICAL INDUSTRIES LTD-2016RR-121113 | RANBAXY | 8.00 | DEC | F | Y | 0.00000 | 20160817 | OT | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126063912 | 12606391 | 1 | SS | PACLITAXEL. | PACLITAXEL | 1 | Intravenous (not otherwise specified) | WEEKLY | U | U | 0 | 100 | MG/M**2 | ||||||
| 126063912 | 12606391 | 2 | PS | GEMCITABINE | GEMCITABINEGEMCITABINE HYDROCHLORIDE | 1 | Unknown | WEEKLY | U | U | 78433 | 1000 | MG/M**2 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126063912 | 12606391 | 1 | Pancreatic carcinoma |
| 126063912 | 12606391 | 2 | Pancreatic carcinoma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126063912 | 12606391 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126063912 | 12606391 | Decreased appetite | |
| 126063912 | 12606391 | Duodenitis haemorrhagic | |
| 126063912 | 12606391 | Enteritis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |